Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems. Having high ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...